Tongkat ali for testosterone: what the standardized-extract trials actually show.

What tongkat ali is, and what the active compounds are

Tongkat ali — Eurycoma longifolia Jack, also called longjack or Malaysian ginseng — is a flowering plant native to Southeast Asia, primarily Malaysia, Indonesia, and Thailand. It has a centuries-long history of use in traditional Malay and Indonesian medicine, primarily as a male vitality and energy tonic. In that tradition, the root was decocted in water and consumed as a bittersweet tea — a preparation method that turns out to be pharmacologically relevant, since the bioactive quassinoids are water-soluble.

The compounds believed to drive the testosterone and cortisol effects fall into three main classes: quassinoids (particularly eurycomanone, 13α,21-dihydroeurycomanone, and eurycomaoside), alkaloids (beta-carboline alkaloids), and glycosaponins. Of these, eurycomanone has the best-characterized mechanism: it appears to inhibit sex hormone-binding globulin (SHBG) binding to testosterone, thereby increasing free testosterone fractions, and may also interact with androgen receptor signaling pathways in vitro [1, 2]. The quassinoids also have documented Leydig cell stimulatory activity in preclinical models — meaning the compound may support the testes' own testosterone production rather than simply freeing what's already circulating [2].

Standardization: why eurycomanone content determines whether you have a supplement or a placebo

This is the most important section for anyone currently taking or evaluating a tongkat ali product. The commercial market is saturated with products making identical dosage claims — 200 mg, 400 mg, "Malaysian-sourced root" — that contain wildly different amounts of the bioactive quassinoids. Without knowing the eurycomanone content, the dose printed on the bottle is essentially meaningless.

The trial data with the most convincing human outcomes — particularly the Tambi group's work and the Physta trials — used extracts standardized to approximately 22% total quassinoids and approximately 2% eurycomanone specifically [3]. Products marketed as "400 mg tongkat ali" that contain uncharacterized root powder standardized only to something vague like "40:1 extract ratio" do not have the same evidence base. A 40:1 concentration ratio tells you how much starting material was used in extraction — it says nothing about what the resulting extract actually contains.

The two most-studied commercial extracts with published RCT data are Physta (standardized aqueous root extract, approximately 22% total quassinoids) and the extract used in the Tambi group's hypogonadism trials (standardized water-soluble extract, similar specification). If a product does not name its extract and does not disclose eurycomanone content, you are guessing.

A 400 mg dose of unstandardized tongkat ali root powder and a 200 mg dose of a properly standardized extract are not the same product. The RCT data belongs to the standardized extract. The gram count on the label is not the variable that matters.

Testosterone signal in hypogonadal men: what the trials show

The most compelling testosterone data comes from trials enrolling men with documented low testosterone — specifically, men meeting clinical criteria for late-onset hypogonadism (LOH), generally defined as total testosterone below approximately 300 ng/dL with associated symptoms.

The landmark trial by Tambi and colleagues enrolled 76 men with LOH who received 200 mg of standardized E. longifolia extract daily for one month [3]. After treatment, 90.8% of subjects showed testosterone levels that normalized into the reference range — from a mean of approximately 5.66 nmol/L to 8.31 nmol/L, roughly a 47% increase in total testosterone. This is a real, meaningful clinical signal. The limitation: no placebo arm. Without a control group, the size of the placebo response — which can be substantial in hormone trials — is uncontrolled.

A better-controlled 6-month study published in Maturitas in 2021 enrolled men with androgen deficiency of aging males (ADAM) in a randomized, placebo-controlled design [4]. Participants (average age ~47 years) received 200 mg/day of standardized extract alongside a concurrent exercise program. After 6 months, the treatment group showed significant improvements in total testosterone and erectile function scores versus placebo. The magnitude was modest but statistically significant, and the trial quality — blinded, controlled, adequate duration — is meaningfully better than most of the earlier literature.

Testosterone signal in eugonadal men: more modest than marketed

Eugonadal men — those with testosterone already in the normal reference range — are the majority of buyers of testosterone-support supplements, and also the population for whom the clinical effect of tongkat ali is the most modest and least reliably demonstrated.

The Talbott 2013 trial in moderately stressed adults (13 men, 12 women) showed a significant cortisol reduction but only a modest free testosterone increase that did not reach the effect sizes seen in hypogonadal trials [5]. A 2022 systematic review and meta-analysis that pooled trials in both healthy volunteers and hypogonadal men concluded that a significant improvement in total testosterone was reported in both groups, but the effect size was consistently larger in the hypogonadal population [6]. In eugonadal men, the testosterone elevation reported across trials is typically in the range of 10 to 20 percent — real, but not the dramatic numbers that supplement marketing implies.

The honest framing: if your testosterone is clinically low, tongkat ali with a properly standardized extract has genuine evidence behind it. If your testosterone is already in the normal range and you're looking for a meaningful boost, the effect is real but modest — and whether that modest shift translates to perceptible changes in energy, libido, or body composition is not established in well-controlled trials.

The under-discussed cortisol signal

The cortisol-modulating effect of tongkat ali is arguably the more interesting clinical signal, and it is almost universally underreported in supplement marketing in favor of the testosterone story. The Talbott 2013 JISSN study enrolled moderately stressed adults and found a 16% reduction in cortisol exposure versus placebo, alongside significant improvements in tension, anger, and confusion scores [5]. These are not small numbers for a botanical.

The mechanism is likely indirect: chronically elevated cortisol suppresses hypothalamic GnRH (gonadotropin-releasing hormone) pulsatility, which in turn reduces LH (luteinizing hormone) and FSH (follicle-stimulating hormone) output from the pituitary and drives down testicular testosterone production. You can read your own LH, FSH, and total testosterone results against reference ranges using the lab interpreter. The GnRH-LH-FSH signaling chain from brain to gonads is extremely sensitive to cortisol. If tongkat ali genuinely reduces cortisol, some of its testosterone-supporting effect may simply be the restoration of normal pituitary drive that chronic stress had suppressed. This is not a criticism of the compound — it is a more complete and honest explanation of the mechanism.

For users who are genuinely stressed and sleep-deprived — a significant overlap with the population using testosterone supplements — the cortisol-lowering effect may explain more of the subjective benefit than the direct testosterone signal. And for that application, the evidence is arguably better. The Talbott trial was placebo-controlled and the effect sizes were substantial.

The dose-response gap: 200 mg versus 400–600 mg

Most mass-market tongkat ali products are sold at 200 mg of standardized extract. Most of the better-controlled clinical trials used 400 mg or higher. This gap matters.

The Physta trials used both 100 mg and 200 mg doses in some older-male populations, with both doses showing testosterone improvements. The 6-month ADAM trial by Leitao and colleagues also used 200 mg/day — the same floor dose as the Tambi hypogonadism study, though the Leitao trial was placebo-controlled and paired with exercise [4]. A separate short-duration trial in young recreationally active men tested 600 mg/day for two weeks and found significant testosterone changes, but the duration is too short to draw dose-response conclusions. In aggregate, 200 mg of well-standardized extract is the most replicated dose; whether 400–600 mg produces meaningfully larger effects in eugonadal men over longer durations is an open question the current literature does not resolve.

The implication for product selection: a product containing 200 mg of well-standardized extract with confirmed eurycomanone content around 2% is likely delivering a real effect. A product containing 400 mg of uncharacterized root powder is not. Dose without standardization is noise.

Women's safety and hormonal effects — the section most coverage skips

The women's safety picture for tongkat ali is genuinely underresearched, and the supplement industry essentially ignores it. The vast majority of tongkat ali trials were conducted exclusively in men. What we know from the available evidence:

The Talbott 2013 stress-hormone trial included 12 women alongside 13 men, and reported cortisol reductions and mood improvements in the combined sample. No sex-stratified hormone analysis was published — so whether the testosterone signal occurred in women is unknown from that study. A small Physta pilot in postmenopausal women showed improvements in DHEA (dehydroepiandrosterone) and free testosterone fractions, but this trial was unpowered for hormone outcomes and should be treated as hypothesis-generating only [7].

The pharmacological concern for women is straightforward: tongkat ali's proposed mechanism includes both SHBG reduction (increasing free testosterone) and potentially direct androgen support. In premenopausal women, that signal interacts with a hormonal environment that includes estrogen, progesterone, and the LH/FSH cycle in ways that simply have not been studied adequately. The cycle phase at time of use is relevant — elevated free testosterone carries different downstream effects depending on whether a woman is in the follicular or luteal phase.

The honest position: for postmenopausal women experiencing the low-energy, low-libido picture that can accompany declining DHEA and free testosterone, tongkat ali has a plausible mechanism and limited but directionally positive pilot data. For premenopausal women, the data is insufficient to make a clear recommendation, and the cortisol-lowering effect may be a safer angle to focus on than the androgen effects.

What is unequivocally clear: pregnant and breastfeeding women should not use tongkat ali. No safety data exists in those populations and the androgenic mechanism is a theoretical concern for fetal development.

One additional safety note: the European Food Safety Authority flagged in 2021 that tongkat ali root extract has demonstrated genotoxic potential in in vitro cell studies — meaning it could potentially cause DNA damage at high doses [8]. This is a preclinical finding, not a clinical outcome in the published human trials, and the doses tested in vitro were higher than typical supplement dosing. But it is a real flag that warrants ongoing monitoring as the evidence base matures.

Practical framing: who benefits, and what to look for on the label

Based on the evidence as it stands, the clearest candidate for tongkat ali supplementation is a man with documented or suspected late-onset hypogonadism who is not yet on prescription testosterone replacement therapy and wants to exhaust non-prescription options first. A standardized extract at 200 mg/day — the most consistently replicated clinical dose — for at least 3 months is the minimum evidence-supported protocol; consult a clinician before starting.

The secondary application — and arguably the one with the cleanest evidence — is chronic stress with elevated cortisol in both men and women. The Talbott data is genuinely impressive for a botanical, and the mechanism is mechanistically coherent and testable.

For eugonadal men looking for meaningful testosterone optimization, the honest answer is that tongkat ali delivers a real but modest effect — in the 10 to 20% range for total testosterone — and whether that translates to perceptible physical or performance changes depends heavily on baseline status, lifestyle factors, and whether the cortisol pathway is the actual driver. It is not a replacement for addressing the upstream causes of testosterone decline: sleep quality, body composition, stress load, and resistance training.

For anyone currently on or considering enclomiphene or hCG protocols for testosterone support, tongkat ali occupies a different tier — botanical support with a real but modest effect compared to those pharmacological interventions. They are not interchangeable.